165 related articles for article (PubMed ID: 23749890)
21. Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer.
Kiesslich T; Mayr C; Wachter J; Bach D; Fuereder J; Wagner A; Alinger B; Pichler M; Di Fazio P; Ocker M; Berr F; Neureiter D
Mol Cell Biochem; 2014 Nov; 396(1-2):257-68. PubMed ID: 25064451
[TBL] [Abstract][Full Text] [Related]
22. Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Umbreit C; Aderhold C; Faber A; Sommer JU; Sauter A; Hofheinz RD; Stern-Sträter J; Hoermann K; Schultz JD
Anticancer Res; 2013 Jun; 33(6):2457-65. PubMed ID: 23749896
[TBL] [Abstract][Full Text] [Related]
23. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.
Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C
Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358
[TBL] [Abstract][Full Text] [Related]
24. Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations.
Dollner R; Granzow C; Neudert M; Dietz A
Anticancer Res; 2006; 26(2B):1651-5. PubMed ID: 16619587
[TBL] [Abstract][Full Text] [Related]
25. Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells.
Shafaee Z; Schmidt H; Du W; Posner M; Weichselbaum R
Cancer Chemother Pharmacol; 2006 Dec; 58(6):765-70. PubMed ID: 16552573
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
Mimeault M; Moore E; Moniaux N; Hénichart JP; Depreux P; Lin MF; Batra SK
Int J Cancer; 2006 Feb; 118(4):1022-31. PubMed ID: 16108016
[TBL] [Abstract][Full Text] [Related]
27. Inhibiting Hedgehog: An Update on Pharmacological Compounds and Targeting Strategies.
Galperin I; Dempwolff L; Diederich WE; Lauth M
J Med Chem; 2019 Sep; 62(18):8392-8411. PubMed ID: 30986059
[TBL] [Abstract][Full Text] [Related]
28. Effect of the Hedgehog-inhibitor cyclopamine on mice with osteosarcoma pulmonary metastases.
Warzecha J; Dinges D; Kaszap B; Henrich D; Marzi I; Seebach C
Int J Mol Med; 2012 Mar; 29(3):423-7. PubMed ID: 22138977
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.
Nör C; Zhang Z; Warner KA; Bernardi L; Visioli F; Helman JI; Roesler R; Nör JE
Neoplasia; 2014 Feb; 16(2):137-46. PubMed ID: 24709421
[TBL] [Abstract][Full Text] [Related]
30. Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926.
Lin TL; Wang QH; Brown P; Peacock C; Merchant AA; Brennan S; Jones E; McGovern K; Watkins DN; Sakamoto KM; Matsui W
PLoS One; 2010 Dec; 5(12):e15262. PubMed ID: 21203400
[TBL] [Abstract][Full Text] [Related]
31. HH/GLI signalling as a new therapeutic target for patients with oral squamous cell carcinoma.
Yan M; Wang L; Zuo H; Zhang Z; Chen W; Mao L; Zhang P
Oral Oncol; 2011 Jun; 47(6):504-9. PubMed ID: 21536478
[TBL] [Abstract][Full Text] [Related]
32. Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Tai SK; Yang MH; Chang SY; Chang YC; Li WY; Tsai TL; Wang YF; Chu PY; Hsieh SL
Cancer Sci; 2011 Apr; 102(4):895-902. PubMed ID: 21219537
[TBL] [Abstract][Full Text] [Related]
33. I only have eye for ewe: the discovery of cyclopamine and development of Hedgehog pathway-targeting drugs.
Chen JK
Nat Prod Rep; 2016 May; 33(5):595-601. PubMed ID: 26787175
[TBL] [Abstract][Full Text] [Related]
34. Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
Wagenblast J; Hambek M; Baghi M; Gstöttner W; Strebhardt K; Ackermann H; Knecht R
J Cancer Res Clin Oncol; 2008 Mar; 134(3):323-30. PubMed ID: 17701215
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
36. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
[TBL] [Abstract][Full Text] [Related]
37. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo.
Wickström M; Dyberg C; Shimokawa T; Milosevic J; Baryawno N; Fuskevåg OM; Larsson R; Kogner P; Zaphiropoulos PG; Johnsen JI
Int J Cancer; 2013 Apr; 132(7):1516-24. PubMed ID: 22949014
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel in the management of patients with head and neck squamous cell carcinoma.
Bernier J; Vrieling C
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1023-32. PubMed ID: 18588449
[TBL] [Abstract][Full Text] [Related]
39. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.
Zhang N; Erjala K; Kulmala J; Qiu X; Sundvall M; Elenius K; Grénman R
Radiother Oncol; 2009 Sep; 92(3):388-92. PubMed ID: 19447510
[TBL] [Abstract][Full Text] [Related]
40. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
